Drug Trial Radar · NCT02686658
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
286
Actual
Start
Dec 15, 2015
Primary completion
Sep 26, 2019
Study completion Apr 23, 2020
Sponsor
- Lead sponsor
- IVERIC bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Conditions
- Geographic Atrophy
- Dry Age-Related Macular Degeneration
Interventions
Avacincaptad PegolDrug
Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection
ShamOther
The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Geographic Atrophy as Measured by Fundus AutofluorescenceTime frame: Baseline and 12 months
Locations
78 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Campbell, California
Site not named
Fresno, California
Site not named
Fullerton, California
Site not named
La Jolla, California
Site not named
Mountain View, California
Site not named
Redlands, California
Site not named
Sacramento, California
Site not named
Sacramento, California
Site not named
Santa Ana, California
Site not named
Denver, Colorado
Site not named
Altamonte Springs, Florida
Site not named
Boynton Beach, Florida
Site not named
Melbourne, Florida
Site not named
St. Petersburg, Florida
Site not named
Stuart, Florida
Site not named
Winter Haven, Florida
Site not named
Augusta, Georgia
Site not named
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Site not named
West Des Moines, Iowa
Site not named
Shawnee Mission, Kansas
Site not named
Wichita, Kansas
Site not named
Baltimore, Maryland
Site not named
Chevy Chase, Maryland
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Grand Rapids, Michigan
Site not named
Henderson, Nevada
Site not named
Reno, Nevada
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Asheville, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Hickory, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Cleveland, Ohio
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.